Cephalexin
- Generic Name
- Cephalexin
- Brand Names
- Keflex
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N3O4S
- CAS Number
- 15686-71-2
- Unique Ingredient Identifier
- 5SFF1W6677
- Background
Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis. Cephalexin was approved by the FDA on 4 January 1971.
- Indication
Cephalexin is indicated for the treatment of certain infections caused by susceptible bacteria. These infections include respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections.
- Associated Conditions
- Bone Infection, Genitourinary tract infection, Otitis Media (OM), Respiratory Tract Infections (RTI), Skin and skin structure infections, Acute Prostatitis
Treatment of Asymptomatic Bacteriuria in Pregnancy
- Conditions
- Bacteriuria (Asymptomatic) in Pregnancy
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Saint Joseph Mercy Health System
- Target Recruit Count
- 13
- Registration Number
- NCT02911662
- Locations
- 🇺🇸
St. Joseph Mercy Hospital, Ypsilanti, Michigan, United States
Antibiotics After Breast Reduction:Clinical Trial With Randomization
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 124
- Registration Number
- NCT02569866
- Locations
- 🇧🇷
Hospital das Clínicas Samuel Libanio, Pouso Alegre, Minas Gerais, Brazil
A Study of Cephalexin Liquid in Healthy Participants
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT02490670
- Locations
- 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico
A Study of Cephalexin Liquid for Pediatrics in Healthy Adults Participants
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT02123472
- Locations
- 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico
A Study of Cephalexin Capsules in Healthy Participants
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT02123446
- Locations
- 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico
A Study of Cephalexin Suspension in Healthy Participants
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT02123459
- Locations
- 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico
A Study of Cephalexin in Healthy Participants
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT02100826
- Locations
- 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT02014558
- Locations
- 🇺🇸
Site US10018, Hershey, Pennsylvania, United States
🇺🇸Site US10015, Chicago, Illinois, United States
🇺🇸Site US10020, Hackensack, New Jersey, United States
The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 300
- Registration Number
- NCT01912651
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Bioequivalence Study of Cephalexin Suspension 250
- Conditions
- Infections, Respiratory Tract
- Interventions
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT01767571
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.